Supplemental figures from Multinucleation and Mesenchymal-to-Epithelial Transition Alleviate Resistance to Combined Cabazitaxel and Antiandrogen Therapy in Advanced Prostate Cancer

Supplemental Figures 1-7. Supplemental Figure 1: This figure shows the results of the dose response of human prostate cancer lines to antiandrogen (Enzalutamide) and Docetaxel (1st line taxane chemotherapy) as single agents and in combination treatment. It also describes the effect of AR variants on prostate cancer cell migration. Supplemental Figure 2: This figures describes the findings on the combined effect of Cabazitaxel ( 2nd line taxane chemotherapy) and Enzalutamie (antiandrogen) on AR expression, cellular localization and transcriptional activity ( target gene expression) in androgen-sensitive prostate cancer cells, VCaP. Supplemental Figure 3: This figure shows the results from confocal microscopy analysis on the cellular localization of AR variants, tubulin expression and nuclear presence in Cabazitaxel-resistant prostate cancer cells. Supplemental Figure 4: This Figure indicates the effect of Cabazitaxel treatment on kinesin protein and mRNA expression in androgen-responsive prostate cancer cells VCaP. Supplemental Figure 5: This Figure shows the results from immunofluorescence for detection of centrosomal amplification (pericentrin) in CRPC 22Rv1 cells after Cabazitaxel and antiandrogen treatment. Supplemental Figure 6: This Figure schematically summarizes the therapeutic regimen/dosing for in vivo treatment of pre-clinical transgenic model of prostate cancer with Cabazitaxel and antiandrogens and the consequences of treatment on body weight. Supplementary Figure 7: This Figure schematically describes the therapeutic dosing regimen of Cabazitaxel treatment in prostate cancer human xenograft model (22Rv1 castration resistant prostate cancer) in vivo. It also provides information on the antitumor effect of treatment on tumor growth and body weight of mice.